Plasma infusion in the treatment of thrombotic thrombocytopenic purpura

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Fifteen of 18 patients with clinically diagnosed or pathologically proven thrombotic thrombocytopenic purpura (TTP) responded favorably to plasma infusions. Thirteen remained alive and well. The amount of plasma necessary to produce control of the disease varied widely. Other modalities of treatment were employed in many of the cases, and may have contributed some benefit. These included plasmapheresis, corticosteroids, and antiplatelet agents. The first indicator of a good response to plasma infusion was a rise in platelet count. Platelet transfusions are contraindicated, since they have been associated with rapid clinical deterioration and death. Since hypervolemia can become a severe problem in TTP patients whose plasma requirement is high, it would be helpful to identify and concentrate the therapeutically active plasma fraction. (E.J. van Slyck, Detroit, USA).

Original languageEnglish
Pages (from-to)9-14
Number of pages6
JournalSeminars in Thrombosis and Hemostasis
Volume7
Issue number1
StatePublished - Jan 1 1981

Fingerprint

Thrombotic Thrombocytopenic Purpura
Therapeutics
Platelet Transfusion
Plasmapheresis
Platelet Aggregation Inhibitors
Platelet Count
Adrenal Cortex Hormones

ASJC Scopus subject areas

  • Hematology

Cite this

Plasma infusion in the treatment of thrombotic thrombocytopenic purpura. / Byrnes, J. J.

In: Seminars in Thrombosis and Hemostasis, Vol. 7, No. 1, 01.01.1981, p. 9-14.

Research output: Contribution to journalArticle

@article{8eda61d4442549558828877f26c66e46,
title = "Plasma infusion in the treatment of thrombotic thrombocytopenic purpura",
abstract = "Fifteen of 18 patients with clinically diagnosed or pathologically proven thrombotic thrombocytopenic purpura (TTP) responded favorably to plasma infusions. Thirteen remained alive and well. The amount of plasma necessary to produce control of the disease varied widely. Other modalities of treatment were employed in many of the cases, and may have contributed some benefit. These included plasmapheresis, corticosteroids, and antiplatelet agents. The first indicator of a good response to plasma infusion was a rise in platelet count. Platelet transfusions are contraindicated, since they have been associated with rapid clinical deterioration and death. Since hypervolemia can become a severe problem in TTP patients whose plasma requirement is high, it would be helpful to identify and concentrate the therapeutically active plasma fraction. (E.J. van Slyck, Detroit, USA).",
author = "Byrnes, {J. J.}",
year = "1981",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "9--14",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Plasma infusion in the treatment of thrombotic thrombocytopenic purpura

AU - Byrnes, J. J.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Fifteen of 18 patients with clinically diagnosed or pathologically proven thrombotic thrombocytopenic purpura (TTP) responded favorably to plasma infusions. Thirteen remained alive and well. The amount of plasma necessary to produce control of the disease varied widely. Other modalities of treatment were employed in many of the cases, and may have contributed some benefit. These included plasmapheresis, corticosteroids, and antiplatelet agents. The first indicator of a good response to plasma infusion was a rise in platelet count. Platelet transfusions are contraindicated, since they have been associated with rapid clinical deterioration and death. Since hypervolemia can become a severe problem in TTP patients whose plasma requirement is high, it would be helpful to identify and concentrate the therapeutically active plasma fraction. (E.J. van Slyck, Detroit, USA).

AB - Fifteen of 18 patients with clinically diagnosed or pathologically proven thrombotic thrombocytopenic purpura (TTP) responded favorably to plasma infusions. Thirteen remained alive and well. The amount of plasma necessary to produce control of the disease varied widely. Other modalities of treatment were employed in many of the cases, and may have contributed some benefit. These included plasmapheresis, corticosteroids, and antiplatelet agents. The first indicator of a good response to plasma infusion was a rise in platelet count. Platelet transfusions are contraindicated, since they have been associated with rapid clinical deterioration and death. Since hypervolemia can become a severe problem in TTP patients whose plasma requirement is high, it would be helpful to identify and concentrate the therapeutically active plasma fraction. (E.J. van Slyck, Detroit, USA).

UR - http://www.scopus.com/inward/record.url?scp=0019522968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019522968&partnerID=8YFLogxK

M3 - Article

C2 - 7195079

AN - SCOPUS:0019522968

VL - 7

SP - 9

EP - 14

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 1

ER -